Melbourne, Australia, 13 October 2015: Neuren Pharmaceuticals (ASX: NEU) today announced that the International Rett Syndrome Foundation (Rettsyndrome.org) has made a financial commitment of up to US$1 million, to continue its support of Neuren’s clinical trials of trofinetide for the treatment of Rett syndrome. Rettsyndrome.org previously supported Neuren’s Phase 2 clinical trial in adults and adolescents with Rett syndrome, which successfully demonstrated clinical benefit from treatment with trofinetide. The benefit observed in the trial encompassed many of the core symptoms of Rett syndrome and was observed in both clinician and caregiver assessments. Neuren has since received orphan drug designation in the United States and the European Union for trofinetide in Rett syndrome.
The US Food and Drug Administration (FDA) has granted Fast Track designation for the development program in the United States. Neuren recently met with the FDA to discuss the remaining development requirements, which provided meaningful guidance for Neuren in all areas of the development program.
NEU Price at posting:
8.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)